Passage Bio Inc.

PASG | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.83

+$0.08 (+1.68%)

At close: Sep 21, 2026, 4:00 PM ET

$4.83

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.68%

(1D)

Rating

Updated: Aug 11, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $15.52M

1D Range

4.67 4.89

52W Range

3.29 20

Valuation (TTM)

PE -0.43

PB 3.48

EV/EBITDA 0.26

Valuation (NTM)

Forward PE N/A

Forward PEG -0.10

Price Target $10

Cash Flow

FCF Yield -215.9%

SBC Adj. FCF Yield -230.7%

SBC Impact -6.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 41.8% | 41.0%

FCF 3Y | 5Y 39.8% | 40.0%

Returns

ROA -143.4%

ROE -218.6%

ROIC -889.9%

Financial Health

Net Cash

$24.16M

Current Ratio 1.22

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to tre...

Sector Healthcare

Industry Biotechnology

Employees 24

IPO Date Feb 27, 2020

Website www.passagebio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Upside

+65.63%

Buy (2)

Hold (3)

Sell (0)

Analyst Details ➞